Prognostic molecular markers in pediatric liver disease - Are there any?

被引：6

作者：

Nielsen, Jon ^{[1
]}

Christensen, Vibeke Brix ^{[1
]}

Borgwardt, Lise ^{[2
]}

Rasmussen, Allan ^{[3
]}

Ostrup, Olga ^{[4
]}

Kjaer, Mette Skalshoi ^{[5
]}

机构：

[1] Copenhagen Univ Hosp, Rigshosp, Dept Paediat & Adolescent Med, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark

[2] Copenhagen Univ Hosp, Rigshosp, Dept Clin Physiol Nucl Med & PET, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark

[3] Copenhagen Univ Hosp, Rigshosp, Dept Surg Gastroenterol, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark

[4] Copenhagen Univ Hosp, Rigshosp, Ctr Genom Med, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark

[5] Copenhagen Univ Hosp, Rigshosp, Dept Hepatol, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2019年 / 1865卷 / 03期

关键词：

Hepatobiliary disease; Children; Diagnostics; Outcome prediction; STELLATE CELL ACTIVATION; SURROGATE END-POINTS; C VIRUS-INFECTION; BILIARY ATRESIA; FATTY LIVER; COLLAGEN DEPOSITION; APOPTOSIS MARKERS; NUCLEAR RECEPTORS; SONIC-HEDGEHOG; POOR-PROGNOSIS;

D O I：

10.1016/j.bbadis.2018.12.018

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pediatric liver disease (PLD) is a major cause of severe morbidity and prolonged hospitalizations in children. Stratifying patients in terms of prognosis remains challenging. The limited knowledge about molecular mechanisms causing and accompanying PLD remains the main obstacle in a search for reliable prognostic biomarkers. A systematic search of MEDLINE via PubMed and Embase via OVID was conducted on studies published between August 2007 and August 2017. Molecular markers with a prognostic potential in terms of survival, need for liver transplantation or disease progression/regression were selected. In general, identified studies were single center smaller case-control studies or case series with a low level of evidence and a high risk of bias. Only 23 studies comprising 898 patients could be included, mostly focusing on biliary atresia, non-alcoholic fatty liver disease, viral hepatitis, and LT; and markers related to morphogenesis and fibrosis. Furthermore, molecular markers in metabolic pathways and inflammation shown to be relevant, however requiring further validation. Hence, further biological and clinical studies are needed to gain greater molecular insight into PLD.

引用

页码：577 / 586

页数：10

共 79 条

[21] Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up [J].